Lantern Pharma (NASDAQ: LTRN) announced that its wholly owned subsidiary, Starlight Therapeutics, has received FDA clearance for an Investigational New Drug (“IND”) application to initiate a Phase Ib/2a clinical trial of STAR-001 (LP-184) in combination with spironolactone for patients with glioblastoma multiforme (“GBM”) at first progression. The study will evaluate safety, tolerability and preliminary efficacy in recurrent GBM, a highly aggressive brain cancer with limited treatment options. STAR-001 is a brain-penetrant DNA-damaging agent designed to exploit DNA repair deficiencies through synthetic lethality, and its effect is enhanced by spironolactone, which induces NER deficiency in tumor cells. The therapy has received both Orphan Drug and Fast Track designations from the FDA. The program builds on data from an ongoing Phase 1a trial and is being advanced using Lantern’s AI-driven RADR(R) platform to identify optimal patient populations and accelerate development timelines.
To view the full press release, visit https://ibn.fm/4pAMg
About Lantern Pharma
Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, time, and failure rate of oncology drug discovery and development. Lantern’s proprietary AI platform RADR(R) uses machine learning and multiomic data to solve complex, billion-dollar drug development challenges. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, Lantern has built a pipeline of promising, clinical stage drug candidates, including molecules that target novel cancer mechanisms and targets.
NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN
About AINewsWire
AINewsWire (“AINW”) is a specialized communications platform with a focus on the latest advancements in artificial intelligence (“AI”), including the technologies, trends and trailblazers driving innovation forward. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, AINW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, AINW brings its clients unparalleled recognition and brand awareness.
AINW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from AINewsWire, text “AI” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit www.AINewsWire.com
Please see full terms of use and disclaimers on the AINewsWire website applicable to all content provided by AINW, wherever published or re-published: https://www.AINewsWire.com/Disclaimer
AINewsWire
Austin, Texas
www.AINewsWire.com
512.354.7000 Office
Editor@AINewsWire.com
AINewsWire is powered by IBN
ONAR (OTCQB: ONAR) was featured in a recent article that discussed its strategy amid the AI…
AI Maverick Intel (OTCID: BINP) recently rebranded and adopted a new strategic direction focused on AI-powered…
Robot Consulting (NASDAQ: LAWR), a Japanese platform service provider specializing in human resource solutions with…
D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave” or the “Company”), a leader in quantum computing systems,…
Wearable Devices (NASDAQ: WLDS, WLDSW), a pioneer in AI-powered neural input technology, is spotlighted in…
D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services,…